Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -84.79% | 266.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.79% | 266.37% | |||
| Cost of Revenue | 3.99% | 1,577.98% | |||
| Gross Profit | -218.65% | 68.18% | |||
| SG&A Expenses | -15.49% | -22.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.15% | -24.98% | |||
| Operating Income | -358.02% | 131.76% | |||
| Income Before Tax | -393.68% | 84.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -394.45% | 84.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -394.45% | 84.86% | |||
| EBIT | -358.02% | 131.76% | |||
| EBITDA | -317.95% | 137.25% | |||
| EPS Basic | -392.57% | 85.12% | |||
| Normalized Basic EPS | -782.94% | 112.35% | |||
| EPS Diluted | -392.57% | 85.12% | |||
| Normalized Diluted EPS | -782.94% | 112.35% | |||
| Average Basic Shares Outstanding | 0.34% | 1.77% | |||
| Average Diluted Shares Outstanding | 0.34% | 1.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||